Title | Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. |
Publication Type | Journal Article |
Year of Publication | 2021 |
Authors | Conteduca V, Ku S-Y, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, Slade M, Gilbertson C, Manohar J, Sigouros M, Wang Y, Dittamore R, Wenstrup R, Mosquera JMiguel, Schonhoft JD, Beltran H |
Journal | NPJ Precis Oncol |
Volume | 5 |
Issue | 1 |
Pagination | 76 |
Date Published | 2021 Aug 12 |
ISSN | 2397-768X |
Abstract | Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss of tumor suppressors RB1, TP53, and PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical studies support a trans-differentiation process, whereby NEPC arises clonally from a prostate adenocarcinoma precursor during the course of treatment resistance. Here we highlight a case of NEPC with significant intra-patient heterogeneity observed across metastases. We further demonstrate how single-cell genomic analysis of circulating tumor cells combined with a phenotypic evaluation of cellular diversity can be considered as a window into tumor heterogeneity in patients with advanced prostate cancer. |
DOI | 10.1038/s41698-021-00211-1 |
Alternate Journal | NPJ Precis Oncol |
PubMed ID | 34385567 |
PubMed Central ID | PMC8361159 |
Grant List | W81XWH-17-1-0653 / / U.S. Department of Defense (United States Department of Defense) / R27CA241486 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) / P50 CA211024 / CA / NCI NIH HHS / United States P50-CA211024 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) / R37 CA241486 / CA / NCI NIH HHS / United States |